TransMolecular, Inc.

22 articles about TransMolecular, Inc.

• Morphotek Inc. Announces Acquisition of Tumor Targeting Assets From TransMolecular, Inc.

  4/5/2011

• TransMolecular, Inc.'s 131I-TM601 Shown to Improve Survival in Recurrent Malignant Glioma

  10/23/2009

• TransMolecular, Inc.'s 131I-TM601 Successfully Localizes to Multiple Tumor Types without Targeting Healthy Tissue

  6/17/2009

• TransMolecular, Inc. Presents New Data Highlighting the Anti-angiogenic and Tumor-targeting Properties of TM601 at American Society of Clinical Oncology Annual Meeting

  6/1/2009

• TransMolecular, Inc. Announces Presentation of Data Highlighting Anti-angiogenic and Tumor-targeting Properties of TM601 at American Society of Clinical Oncology Annual Meeting

  5/21/2009

• TransMolecular, Inc. Presents New Information on Distinct Anti-Angiogenic Mechanism-of-Action of TM601

  5/4/2009

• TransMolecular, Inc. Announces Presentation of Data Confirming Anti-angiogenic Method-of-Action of TM601 at ARVO Annual Meeting

  4/30/2009

• TransMolecular, Inc. Appoints Robert Radie President and Chief Executive Officer

  4/7/2009

• TransMolecular, Inc. Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma

  12/22/2008

• TransMolecular, Inc. Reaches Special Protocol Agreement with FDA for an 131I-TM601 Phase 3 Trial in Newly Diagnosed Glioblastoma Multiforme Patients

  12/2/2008

• Radioactive Scorpion Venom Could Be Used To Fight Brain Cancer, University of Chicago Study; Dosing Began In TransMolecular, Inc.'s Phase 1/2 Clinical Trial Of 131I-TM601

  10/2/2008

• Dosing Initiated In TransMolecular, Inc.’s Phase 1/2 Clinical Trial For Intravenous Administration Of 131Iodine-TM601 In Patients With Recurrent Malignant Glioma

  9/29/2008

• TransMolecular, Inc. Presents Imaging and Pharmacokinetic Analysis of 131Iodine-TM601 at Society for Nuclear Medicine Meeting

  6/17/2008

• TransMolecular, Inc. Reports Positive Results from Phase 1 Trial of 131Iodine-TM601 in Metastatic Melanoma

  6/2/2008

• TransMolecular, Inc. Initiates Phase 1 Clinical Trial for Unlabeled TM601 in Recurrent Malignant Glioma

  5/30/2008

• TransMolecular, Inc. Unveils First Data on TM601 Anti-Angiogenic Mechanism-of-Action at American Association for Cancer Research Annual Meeting

  4/14/2008

• TransMolecular, Inc. Receives Orphan Drug Designation for Non-radiolabeled TM601 for the Treatment of Malignant Glioma

  1/7/2008

• TransMolecular, Inc. Reports Positive Phase 2 Data from Study of (131)Iodine Radiolabeled TM-601 in Recurrent Glioma

  11/19/2007

• TransMolecular, Inc. Reports Positive Phase 1 Trial of 131Iodine Radiolabeled TM-601 in Glioma

  10/31/2007

• TransMolecular, Inc. Announces Formation of Medical Advisory Board

  10/24/2007